Pfizer's vaccine 'very promising' but has 'cold chain challenges', says WHO
The World Health Organization's (WHO) chief said on Tuesday it hopes to have a Covid-19 vaccine by year-end and that Pfizer's experimental remedy is "a very promising one", with more expected.
But the vaccine, based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, comes with special challenges as it needs to be stored at minus 70° Celsius or below - equivalent to an Antarctic winter.
WHO Director-General Tedros Adhanom Ghebreyesus reiterated the United Nations agency's call for an equitable distribution of vaccine doses once they are available.
Pfizer said on Monday that its Covid-19 vaccine was more than 90% effective as it disclosed the first successful interim data from a large-scale clinical test. The safety data on its vaccine with BioNTech SE could come later this month.
Pfizer announces that the first data shows that its Covid-19 vaccine trial is more than 90% effective. The vaccination consists of two injections 21 days apart and these types of vaccines are safe and easy to produce. Here's what we know so far.
"As we have been predicting, we will have a vaccine at the end of this year. And the Pfizer one is a very promising one," Tedros told the WHO's annual ministerial meeting.
"And we will also expect more and more," he added.
However, the necessity to keep the vaccine in extremely cold storage could complicate any inoculation programme, above all in regions of Asia or Africa where the climate is warm, distances vast and the required infrastructure may be lacking.
"The exciting news yesterday (Monday) of a possible effective vaccine becoming available presages significant cold chains challenges for African countries by the type of vaccine that that is. Which will need to be factored into the support to be provided," Matshidiso Moeti, WHO's regional director for Africa, told the ministerial meeting.